Joel E. Tepper, MD, on Radiotherapy in Liver and Pancreatic Cancers
2015 ASTRO Annual Meeting
Joel E. Tepper, MD, of the University of North Carolina School of Medicine, discusses the ways in which SBRT has changed radiotherapy, as demonstrated in key studies presented at this year's meeting on stereotactic body radiotherapy for liver metastases and hepatocellular carcinoma, and borderline resectable and unresectable pancreatic tumors (Abstracts 253, 255, 351, 357).
Anthony Zietman, MD
Anthony Zietman, MD, of Massachusetts General Hospital, discusses his perspective on the study of bicalutamide during and after radiotherapy in patients following radical prostatectomy and a biochemical relapse (Abstract LBA5).
Robert Kuske, MD
Robert Kuske, MD, of Arizona Breast Cancer Specialists, discusses the evaluation of more than 1,300 patients with accelerated partial-breast irradiation via multicatheter interstitial brachytherapy, focusing on toxicity and cosmetic outcomes (Abstract 133).
Anthony Zietman, MD
Anthony Zietman, MD, of Massachusetts General Hospital, discusses the practice-changing results from a study comparing fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).
James B. Yu, MD
James B. Yu, MD, of Yale School of Medicine, summarizes the plenary lecture on results from the NRG Oncology/phase III study comparing two fractionation schedules for low-risk prostate cancer (Abstract LBA6).
Anita Mahajan, MD
Anita Mahajan, MD, of MD Anderson Cancer Center, summarizes results from three clinical trials on radiation therapy for ependymoma, locally advanced thoracic esophageal squamous cell carcinoma, and meningioma (Abstracts 31, 1, 7).
